Entrada Therapeutics Q2 collaboration revenue drops, net loss widens
Overview
Entrada Therapeutics Q2 net loss of $43.1 mln vs. net income last yr
Collaboration revenue drops sharply to $2 mln from $94.7 mln last yr
Cash position at $354 mln, sufficient to fund operations into Q2 2027
Outlook
Company expects cash runway to last into Q2 2027
Entrada anticipates reporting ELEVATE-44-201 data in H1 2026
Company plans regulatory submission for ENTR-601-50 in Q4 2025
Entrada expects ELEVATE-45-201 data readout in mid-2026
Result Drivers
CLINICAL TRIAL PROGRESS - First patient dosed in ELEVATE-44-201 and multiple sites activated for ELEVATE-45-201
R&D EXPENSES - Increased costs due to advancement of Duchenne muscular dystrophy programs
COLLABORATION REVENUE DROP - Sharp decline in revenue attributed to completion of Vertex collaboration activities
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Collaboration Revenue | $1.95 mln | ||
Q2 EPS | -$1.04 | ||
Q2 Net Income | -$43.10 mln | ||
Q2 Income From Operations | -$46.85 mln | ||
Q2 Operating Expenses | $48.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Entrada Therapeutics Inc is $20.50, about 71.6% above its August 5 closing price of $5.83
Press Release: